CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 122-128

  Chen, Mei Hsi ^a,b   Atenafu, Eshetu ^b   Craddock, Kenneth J ^b   Brandwein, Joseph ^b   Chang, Hong ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c NANCHANG UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; CD11b; Complex karyotype; Monosomal karyotype

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GENETIC CORRELATION; GENETIC MARKER; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONOSOMAL KARYOTYPE; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL PREDICTION; SURVIVAL TIME;

ABNORMAL KARYOTYPE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD11B; FEMALE; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONOSOMY; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 84872404488     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.09.019     Document Type: Article

References (38)

1. Grimwade D., Hills R.K., Morrman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116(3):354-365.
2. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
3. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
4. Breems D.A., Van Putten W.L.J., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26(29):4791-4797.
5. Medeiros B.C., Othus M., Fang M., Roulston D., Appelbaum F.R. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010, 116(13):2224-2228.
6. Perrot A., Luquet I., Pigneux A., et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 2011, 118(3):679-685.
7. Oran B., Dolan M., Cao Q., Brunstein C., Warlick E., Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogenic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2011, 17:356-364.
8. Fang M., Storer B., Estey E., et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011, 118:1490-1494.
9. Gaillard J.B., Chiesa J., Reboul D., et al. Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion. Leuk Lymphoma 2012, 53(2):336-337.
10. Kayser S., Zucknick M., Döhner K., et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012, 119(2):551-558.
11. Haferlach C., Alpermann T., Susanne S., et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2012, 119:2122-2125.
12. Griffin J.D., Davis R., Nelson D.A., et al. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 1986, 68:1232-1241.
13. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. S.H. Swerdlow, E. Capo, N.L. Harris (Eds.).
14. Ossenkoppele G.J., van de Loosdrecht A.A., Schuurhuis G.J. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol 2011, 153(4):421-436.
15. Mason K.D., Juneja S.K., Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?. Blood Rev 2006, 20(2):71-82.
16. Kita K., Miwa H., Nakase K., et al. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood 1993, 81:2399-2405.
17. Venditti A., Del Poeta G., Buccisano F., et al. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia 1998, 12:1056-1063.
18. Geller R.B., Zahurak M., Hurwitz C.A., et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 1990, 76(3):340-347.
19. Solary E., Casasnovas R.O., Campos L., et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+ CD34+ and CD14+/DR - phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992, 6:393-399.
20. Lauria F., Raspadori D., Ventura M.A., et al. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Stem Cells 1995, 13(4):428-434.
21. Chang H., Slama F., Yi Q., Patterson B., Brien B., Minden M.D. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004, 28:43-48.
22. Tucker J., Dorey E., Gregory W.M., et al. Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. Hematol Oncol 1990, 8(1):47-58.
23. Bradstock K., Bishop J., Matthews J., Benson E., Page F., Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994, 84:1220-1225.
24. Tien H.F., Wang C.H., Lin M.T., et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995, 84:60-68.
25. Raspadori D., Damiani D., Lenoci M., et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001, 15:1161-1164.
26. Campos L., Guyotat D., Archimbaud E., et al. Surface marker expression in adult acute myeloid leukemia: correlations with initial characteristics, morphology and responses to therapy. Br J Haematol 1989, 72:161-166.
27. Schwarzinger I., Valent P., Koller U., et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990, 8:423-430.
28. An international system for human cytogenetic nomenclature 1995, Karger, Basel. D.C. Harnden, H.P. Klinger (Eds.).
29. Graf M., Reif S., Kröll T., Hecht K., Nuessler V., Schmetzer H. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis. Am J Hematol 2006, 81(4):227-235.
30. Paietta E., Andersen J., Yunis J., et al. Acute myeloid leukaemia expressing the leucocyte integrin CD11b - a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Br J Haematol 1998, 100:265-272.
31. Al-Mawali A., Gillis D., Hissaria P., Lewis I. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 2008, 129(6):934-945.
32. Terstappen L.W., Safford M., Konemann S., et al. Flow cytometric characterization of acute myeloid leukemia. Part II: phenotypic heterogeneity at diagnosis. Leukemia 1992, 6(1):70-80.
33. Arnaout M.A. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990, 75:1037-1050.
34. Solovjov D.A., Pluskota E., Plow E.F. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem 2005, 280(2):1336-1345.
35. Diamond M.S., Staunton D.E., de Fougerolles A.R., et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 1990, 111:3129-3139.
36. Beller D.I., Springer T.A., Schreiber R.D. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med 1982, 156:1000-1009.
37. Carlos T.M., Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 1994, 84:2068-2101.
38. Ahn G., Tseng D., Liao C., Dorie M.J., Czechowicz A., Brown J.M. Inhibition of Mac-1 (CD11b/CD18) enhances tumour responses to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA 2010, 107(18):8363-8368.